Stockscreener 앱 받기
24.61
6.77%
1.56
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Truist maintains Buy on Summit Therapeutics, $35 target By Investing.com - Investing.com Canada
Top 3 Health Care Stocks You May Want To Dump This Quarter - Benzinga
Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Monday? - MSN
U.S. Indexes Rose Monday; Summit Therapeutics Led Increases - Barron's
Here's Why Summit Therapeutics Stock Soared 15% on Friday - MSN
Summit Therapeutics (NasdaqGM:SMMT) Welcomes Robert LaCaze As New Chief Commercial Officer - Yahoo Finance
Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition (SMMT) - Seeking Alpha
Why Summit Therapeutics Inc. (SMMT) Surged On Friday? - MSN
Top 3 Biotech Stocks That Got Retail Street Buzzing Last Week: SMMT, PTN, RXRX - MSN
Gold Related Large-Cap Stocks Outperformed In One Of The Most Volatile Weeks (Apr 7-Apr 11): Are These In Your Portfolio? - Benzinga
Why Summit Therapeutics Inc. (SMMT) Soared Last Week? - Insider Monkey
10 Firms Defy Market Slump, Record Double-Digit Gains Last Week - Insider Monkey
3 Magnificent Stocks That Could Double or More by 2030 - Yahoo Finance
Summit Therapeutics spikes after co-CEO’s early warrants exercise - MSN
Summit Therapeutics: Not Pharmacyclics, Not Yet - Seeking Alpha
Gold, Biopharma Firms Dominate Friday’s 10 Top Performing Stocks - Insider Monkey
U.S. Indexes Moved Upward Friday; Summit Therapeutics Led Increases - Barron's
Summit co-CEO option exercise ‘quite bullish,’ says Cantor Fitzgerald - Yahoo Finance
Expert says Summit’s HARMONi-2 study could beat expectations, says Truist - Yahoo Finance
Summit Therapeutics (SMMT) Grants Stock Options to New Employees - GuruFocus
Summit Therapeutics (SMMT) Shows Resilient Cash Management Amid Challenges - GuruFocus
Why Summit Therapeutics Inc. (SMMT) Went Up On Thursday? - Insider Monkey
Summit Therapeutics (SMMT) Sees Stock Surge Amid Early Warrant E - GuruFocus
10 Firms Buck Thursday’s Market Bloodbath - Insider Monkey
Summit Therapeutics (SMMT) Shares Surge After Insider Actions - GuruFocus
Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the Markets - MSN
Summit Therapeutics Shares Surge Amid Study Optimism - TipRanks
Summit Therapeutics (SMMT) Expected to Deliver Strong Results fr - GuruFocus
Summit Therapeutics (SMMT) Sees Bullish Surge as Co-CEO Exercise - GuruFocus
Summit Therapeutics stock gains on insider buy (SMMT:NASDAQ) - Seeking Alpha
Truist maintains Buy on Summit Therapeutics, $35 target - Investing.com
Cantor Fitzgerald maintains Overweight on Summit Therapeutics - Investing.com
Summit Therapeutics Co-CEOs Make Bold Stock Purchases! - TipRanks
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit - Yahoo Finance
Optimistic Buy Rating for Summit Therapeutics Driven by Promising HARMONi-2 Trial and Favorable Regulatory Pathway in China - TipRanks
2 Stocks That Have More Than Doubled in the Past Year to Buy and Hold for a Decade - Yahoo Finance
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Summit Therapeutics Inc.SMMT - MarketScreener
We Think Summit Therapeutics (NASDAQ:SMMT) Can Easily Afford To Drive Business Growth - Yahoo Finance
(SMMT) Technical Data - news.stocktradersdaily.com
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Summit Therapeutics Agrees to $127K Settlement in Wage Dispute - USA Herald
Summit Therapeutics Strengthens Team with Strategic Stock Options Worth $3.4M - Stock Titan
Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Summit Therapeutics (SMMT) Surpasses Nvidia with High Hopes for Cancer Drug - GuruFocus
3 Growth Stocks That Have Dwarfed Nvidia's Returns Over the Past 12 Months - Yahoo Finance
Chinese Biotech Eyes US Nod for Cancer Therapy Eluding Merck - Bloomberg.com
1.27%
자본화:
|
볼륨(24시간):